Latest Innovation News

Constellation Technologies Limited reports sustained sales growth and positive cash flow in Q3 2025, driven by its Callisto Food Safety & Compliance system and strategic market expansion.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Beonic Limited reported a 6.5% increase in annual recurring revenue to $17.8 million and a significant gross margin improvement to 75.5%, driven by new global contracts and disciplined cost management. The company targets cash flow breakeven in Q4 FY25 and an EBITDA margin of up to 15%.

Nexus Minerals has raised A$8.1 million through an institutional placement led by North American investors, boosting its cash reserves to over A$12 million to accelerate exploration at the Wallbrook Gold Project in Western Australia.

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Wide Open Agriculture has inked an exclusive 18-month distribution agreement with Univar Solutions China to market its lupin protein products, marking a strategic push into the lucrative Chinese plant-based protein sector.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.

Hartshead Resources has submitted a revised development plan for its Anning and Somerville gas fields, featuring a superior export route via CalEnergy's Saturn Banks pipeline. Supported by a strong cash position and committed partners, the company is exploring innovative funding to optimise project economics.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.